報價延遲最少15分鐘:2025/06/03 17:36 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
46.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.41/-2.65
|
|
企業價值
3.52B
|
| 資產負債 |
|
每股賬面淨值
5.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
191.59M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 17:36 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor. |